METHOD FOR PREDICTION OF RISK OF PROGRESSION OF FOCAL PULMONARY FIBROSIS IN CHILDREN WITH CHRONIC NON-SPECIFIC PULMONARY DISEASES Russian patent published in 2024 - IPC A61B5/00 C12Q1/6827 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to paediatrics, pulmonology, and can be used to predict the risk of progression of focal pneumofibrosis in children with chronic non-specific pulmonary diseases. A total score (TS) of medical and social indicators is calculated: living in an urban area, the presence of passive smoking, a pulmonary history of 4–9 years, presence of congenital malformation of lungs, number of acute respiratory infections 4 or more times a year, duration of acute respiratory infections 11 days or more, taking antibiotics 3 or more times a year, as well as presence of deletions in detoxification genes GSTM1 and GSTT1. Points are assigned: living in an urban area: there is sign – 1 point, the absence of sign – 0 points; passive smoking: there is sign – 1 point, the absence of sign – 0 points; duration of pulmonary history is 4–9 years: there is sign – 1 point, pulmonological history of 1–3 years or more than 10 years – 0 points; presence of congenital malformation of lungs: there is sign – 1 point, absence of sign – 0 points; number of acute respiratory infections is 4 or more times a year: there is sign – 1 point, the absence of sign – 0 points; duration of acute respiratory infections is 11 days or more: there is sign – 1 point, the absence of sign – 0 points; taking antibiotics 3 or more times a year: there is sign – 1 point, the absence of sign – 0 points; presence of deletions in genes GSTM1 and GSTT1: the absence of sign – 0 points, GSTM1del – 1 point, GSTT1del – 1 point, deletion genotype in genes GSTM1+GSTT1 – 2 points. If the TS value is 6.97 and more, a high risk of progression of focal pneumofibrosis is predicted. If TS 3.47–6.96 points, moderate risk of progression of focal pneumofibrosis is diagnosed. If TS is 3.46 and less, there is a minimum risk of progression of focal pneumofibrosis.

EFFECT: method enables to obtain criteria for predicting the risk of progression of focal pneumofibrosis in children with chronic pulmonary diseases based on detection of medical and social risk factors and determination of polymorphisms of detoxification genes GSTM1 and GSTT1 for timely correction of detected disorders.

1 cl, 2 tbl, 3 ex